Amniotics AB (publ) announced that safety has been established in the second cohort of the completed Phase Ib clinical trial investigating the lung-specific stem cell therapy PulmoStem in hospitalized patients with severe respiratory infections caused by COVID-19, RSV or other viral infections. The study dose escalation committee has announced that no dose-limiting safety findings were noted in the second dose level of two million cells per kilogram of body weight. The company has previously announced that the study ended after the second dose level and that the study report is expected to be ready in the third quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0038 SEK | 0.00% | 0.00% | -57.78% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-57.78% | 947K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AMNI Stock
- News Amniotics AB
- Amniotics AB Receives Positive Information About Safety Data for PulmoStem in Clinical Study